Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenascienceTSE:4889 -2.25%53 Altman Z-Score is 70.09 as of Jul. 17, 2026, which is 366% above its 10-year median of 15.04. GuruFocus rates TSE:4889 with a GF Score™ of 53/100 and a GF Value™ of 円331.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 808 Medical Devices & Instruments companies, Renascience ranks better than 99.13% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 69.04 is strong.
Renascience has a Altman Z-Score of 70.09, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Renascience's Altman Z-Score or its related term are showing as below:
TSE:4889'
s Altman Z-Score Range Over the Past 10 Years
Min: 6.21 Med: 15.04 Max: 77.23
Current: 69.04
During the past 7 years, Renascience's highest Altman Z-Score was 77.23. The lowest was 6.21. And the median was 15.04.
Renascience (TSE:4889) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Renascience Altman Z-Score Related Terms
Renascience Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Renascience's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4889 vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, Renascience's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renascience Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Renascience's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Renascience's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Renascience's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9484
+
1.4
*
-0.3244
+
3.3
*
-0.0857
+
0.6
*
116.1132
+
1.0
*
0.0196
=
70.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Renascience (TSE:4889) has a Altman Z-Score of 70.09 as of Jul. 17, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Renascience and its competitors. This is 366% above median its historical median of 15.04. Over the past decade, Renascience's Altman Z-Score has ranged from 6.21 to 77.23. According to the industry distribution chart, Renascience ranks #7 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 0.90000000000001%.
Is Renascience's Altman Z-Score too high?
Renascience's current Altman Z-Score of 70.09 is 366% above median its 10-year median of 15.04. Over the past 10 years, this metric has ranged from a low of 6.21 to a high of 77.23. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. Renascience's value of 70.09 is 2224.7% above this industry median. Based on the distribution chart, Renascience ranks #7 out of 808 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Renascience has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Renascience ranks #7 out of 808 companies for Altman Z-Score. This places Renascience in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.02. Renascience's value of 70.09 is 2224.7% above this benchmark. Historically, Renascience's own Altman Z-Score has ranged from 6.21 to 77.23 over the past decade. While the company's 10-year median is 15.04 vs. the industry median of 3.02, Renascience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renascience's current Altman Z-Score of 70.09 is 2224.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Renascience and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renascience's current Altman Z-Score is 70.09, which is 366% above median its own 10-year median of 15.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円331.42, compared to a current price of 円1,522.00 — trading 359.2% above its estimated fair value. The current Altman Z-Score is 70.09, which is 366% above median its 10-year median of 15.04 and 2224.7% above the Medical Devices & Instruments industry median of 3.02. Renascience's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Renascience (TSE:4889), the current Altman Z-Score is 70.09 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renascience (TSE:4889) Overvalued in 2026?
Based on GuruFocus' analysis, Renascience stock appears to be overvalued.
The current stock price of 円1,522.00 is trading 359.2% above its estimated GF Value™ of 円331.42.
GuruFocus considers Renascience to be Significantly Overvalued.
Key valuation signals for TSE:4889:
Altman Z-Score: 70.09 (366% above median its 10-year median of 15.04)
GF Value™: 円331.42 vs. price of 円1,522.00 (359.2% above fair value)
Industry Position: 2224.7% above the Medical Devices & Instruments median (#7 of 808)
No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
53GF Score
Get the complete analysis for TSE:4889
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4889 has been successfully added to your 
